类风湿关节炎靶向治疗新时代  

Targeted Therapy for Rheumatoid Arthritis in the New Era

作　　者：王郡 孟娟[1] WANG Jun;MENG Juan(Rheumatology and Immunology Department,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院风湿免疫科,北京100020

出　　处：《协和医学杂志》2025年第1期19-27,共9页Medical Journal of Peking Union Medical College Hospital

摘　　要：类风湿关节炎(rheumatoid arthritis,RA)是一种慢性全身性自身免疫性疾病,表现为关节内外、器官及系统受累,临床异质性强,但发病机制仍不明确。关节炎症明显且药物治疗效果不佳的患者可出现肢体残疾,严重影响生活质量。近年来,RA的靶向治疗成为研究热点并取得了突破性进展。本文对RA靶向药物(包括生物制剂类和小分子靶向合成改善病情抗风湿药物)的研究现状及进展加以阐述,以期为临床医生提供思路,更好地指导RA患者的个体化治疗。Rheumatoid arthritis(RA)is a chronic systemic autoimmune disease.The clinical manifestation of RA involves various organs and systems both inside and outside the joints,and often exhibits strong clinical heterogeneity with unclear pathogenesis.Ineffective drug treatment for severe arthritis can result in physical disability and severely decreased quality of life.In recent years,targeted therapy for RA has become a hot research topic and has made new breakthroughs.Targeted treatments for RA mainly include two categories:biologic and targeted synthetic disease-modifying antirheumatic drugs.This article aims to elaborate on the current research status and progress of these drugs,with the hope of providing insights for clinicians to better guide personalized treatment for RA patients.

关 键 词：类风湿关节炎 靶向治疗 生物制剂 小分子靶向药物 

分 类 号：R593.22[医药卫生—内科学] R749.053[医药卫生—临床医学]